TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05118373

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA
Description: The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
Study: NCT05434741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Group Skills
Description: The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-time Trifold Brochure titled HIV: 50 Years or Older
Description: Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group.
Study: NCT06333366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-gastrointestinal monitoring device (PDT)
Description: The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
Study: NCT05860153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Group with oral levetiracetam at a dose of 15-20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Group with diazepam at a dose of 0.3 mg/kg/dose
Study: NCT05938673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation- intermittent theta-burst (iTBS) stimulation
Description: During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
Study: NCT05852509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TPA4You
Description: TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
Study: NCT06400160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB511
Description: TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.

Intervention type: DRUG
Group type: OTHER
Intervention: Keytruda
Description: KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
Study: NCT05677373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRD4 Inhibitor PLX2853
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT with contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI with contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen collection
Description: Correlative studies
Study: NCT06079606

Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.

Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.

Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
Study: NCT05889780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food pantry referrals
Description: Clients receive food for up to 21 meals per person in the household each month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food pantry referrals
Description: Clients receive food for up to 21 meals per person in the household each month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food pantry referrals
Description: Clients receive food for up to 21 meals per person in the household each month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-prep, ready-to-eat meals
Description: 12 nutritious no-prep, ready-to-eat meals are provided each month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vouchers
Description: A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
Study: NCT05733208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-remote ischemic preconditioning
Description: The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
Study: NCT06234501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate (100 mg)
Description: 100 mg Pyridoxal 5'-Phosphate tablet once daily with food

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT05843877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy
Description: Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)
Description: As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
Study: NCT05617716

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional external beam radiation therapy dose (EBRT)
Description: Participants will undergo 8 Gray in 1 fraction of EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spine radiosurgery/stereotactic body radiation therapy standard dose
Description: Participants will undergo 24 Gray in 2 fractions of SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spine radiosurgery/stereotactic body radiation therapy high dose
Description: Participants will undergo 19 Gray in 1 fraction of SBRT
Study: NCT05805306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entre Herman@s
Description: The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccines for Health
Description: The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
Study: NCT05239390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCI -110
Description: Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis.
Study: NCT06417658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Supraorbital Eyebrow Craniotomy
Description: The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Frontal Craniotomy
Description: The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
Study: NCT05775666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCLM802 Cell Injection
Description: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
Study: NCT04823494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Earbud style hearing aids fit to both ears

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Earbud style hearing aids fit to both ears
Study: NCT04657627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE plus calorie labelling information
Description: The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-only labelling information
Description: The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
Study: NCT05901766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UNIMAP Multiple Micronutrient Supplement
Description: Iodine Containing Multiple Micronutrient Supplement once daily
Study: NCT06513481

Intervention type: DRUG
Intervention: Nardraparin calcium injection
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day

Intervention type: DRUG
Intervention: Nardraparin calcium injection
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
Study: NCT06370611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early mobile health intervention supplemented by weekly calls from a physiotherapist
Description: Six-week home-based rehabilitation program using the ICURA app and sensor-based technology (ICURA ApS, Copenhagen, Denmark). During the hospital stay patients in the intervention group are introduced to the app's usage, and an individualized training plan is collaboratively created and subsequently tailored by a physiotherapist.~The comprehensive mobile health intervention includes customized training programs, activity tracking, visualization of exercises with videos, and a password-protected webpage for physiotherapists to customize training programs and track patient activity.~The patients will receive two calls from a physiotherapist per week for the first two weeks and as required the following four weeks.
Study: NCT04793113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FreshlyFit Meals
Description: FreshlyFit meals are low carbohydrate, high protein meals
Study: NCT04422301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: an alternative method to produce strength and muscle hypertrophy with lower intensities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: an alternative method to produce strength and muscle hypertrophy with lower intensities
Study: NCT06281964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: Participants received oral PLB1004 240mg on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 240mg and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
Description: Participants received IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 and 500 mg/m\^2 of pemetrexed on Day 1 q3w and Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. until disease progression in the maintenance period.
Study: NCT05852509

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention control group
Description: Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
Study: NCT06662747

Intervention type: DIAGNOSTIC_TEST
Intervention: None - observational study only
Description: No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
Study: NCT06188949

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dolichos biflorus (Horsegram) seed extract
Description: 1 capsule twice a day (Before breakfast \& dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carica papaya leaves extract
Description: 1 capsule twice a day (Before breakfast \& dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MCC)
Description: 1 capsule twice a day (Before breakfast \& dinner)
Study: NCT05370300

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
Study: NCT04794491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-258
Description: Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
Study: NCT04725864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal tablet
Description: The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal tablet
Description: The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
Study: NCT05957315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Cardiac Outpatient Telemetry Device (MCOT)
Description: Application of a Philips/Biotel MCOT device